Development of an interface to refer OMICS information into clinic

• Project/Area Number: 25670703
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Obstetrics and gynecology
• Research Institution: Kinki University
• Principal Investigator: MANDAI Masaki 近畿大学, 医学部, 教授 (80283597)
• Co-Investigator(Kenkyū-buntansha): SHIMIZU Akira 京都大学, 医学部, 教授 (00162694) ; YAMADA Ryo 京都大学, 医学部, 教授 (50301106)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 卵巣癌 / マイクロアレイ / 細胞内シグナル / バイオインフォマティクス / インターフェース / マイクロアレイ解析 / バーチャルカルテ

Outline of Final Research Achievements

Virtial chart for this study was　created　in　the　main　computer　to　stock　patient　information　safely.　All　the　clinical　and　bioinformatics data except for personal identification were stored. Ovarian cancer specimen was subjected to the analysis of microarray in inhouse facility and all the data was stored in the main computer. Then, intracellular signals of each sample was calculated and　refined　into　1　to　10　scores,　so　that　enables　to　estimate　what　kind　of　intracellular　signal was activated in individual patient. These analysis was performed in a routine manner.

Research Products

• [Journal Article] The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-a potential therapeutic target. (2015)
  • Author(s): Peng J, Yoshioka Y, Mandai M, et al
  • Journal Title: Mol Carcinog Volume: Epub ahead of print Issue: 4 Pages: 1-11
  • DOI: 10.1002/mc.22283
  • Peer Reviewed / Open Access
• [Journal Article] Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. (2015)
  • Author(s): Nagura M, Matsumura N, Baba T, Murakami R, Kharma B, Hamanishi J, Yamaguchi K, Abiko K, Koshiyama M, Mandai M, et al.
  • Journal Title: Gynecol Oncol Volume: 136 Issue: 1 Pages: 104-111
  • DOI: 10.1016/j.ygyno.2014.11.075
  • Peer Reviewed / Open Access
• [Journal Article] Epigenetic determinants of ovarian clear cell carcinoma biology. (2013)
  • Author(s): Yamaguchi K, Huang Z, Matsumura N, Mandai M, Okamoto T, Baba T, Konishi I, Berchuck A, Murphy SK.
  • Journal Title: Int J Cancer. Volume: - Issue: 3 Pages: 585-97
  • DOI: 10.1002/ijc.28701
  • Peer Reviewed / Open Access
• [Journal Article] Hepatocyte nuclear factor-1β promotes glucose uptake and glycolytic activity in ovarian clear carcinoma (2013)
  • Author(s): T Okamoto, M Mandai, N Matsumura, K Yamaguchi, H Kondoh, Y Amano, T Baba, J Hamanishi, K Abiko, K Kosaka, S K, Murphy, S Mori, I Konishi
  • Journal Title: Molecular carcinogenesis Volume: Sep 17 Issue: 1 Pages: 1-15
  • DOI: 10.1002/mc.22072
  • Peer Reviewed
• [Journal Article] Utilization of genomic signatures to identify high efficacy candidate drugs for chemo-refractory endometrial cancers. (2013)
  • Author(s): Kharma B, Baba T, Mandai M, Matsumura N, Murphy SK, Kang HS, Yamanoi K, Hamanishi J, Yamaguchi K, Yoshioka Y, Konishi I.
  • Journal Title: Int J Cancer. Volume: 133 Issue: 9 Pages: 2234-44
  • DOI: 10.1002/ijc.28220
  • Peer Reviewed
• [Journal Article] PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction. (2013)
  • Author(s): Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma B, Kosaka K, Konishi I.
  • Journal Title: Clin Cancer Res. Volume: 19 Issue: 6 Pages: 1363-1374
  • DOI: 10.1158/1078-0432.ccr-12-2199
  • Peer Reviewed
• [Presentation] 卵巣高悪性漿液性腺癌のmolecular subtypeを反映する新しい病理組織学的分類
  • Author(s): 村上隆介、ほか
  • Organizer: 第66回日本産科婦人科学会
  • Place of Presentation: 東京
• [Presentation] がん薬物療法の未来
  • Author(s): 万代昌紀
  • Organizer: がん分子標的治療フォーラム
  • Place of Presentation: 岡山
  • Invited